WO2017168877A1 - Manufacturing method for tissue-paper product - Google Patents

Manufacturing method for tissue-paper product Download PDF

Info

Publication number
WO2017168877A1
WO2017168877A1 PCT/JP2016/088025 JP2016088025W WO2017168877A1 WO 2017168877 A1 WO2017168877 A1 WO 2017168877A1 JP 2016088025 W JP2016088025 W JP 2016088025W WO 2017168877 A1 WO2017168877 A1 WO 2017168877A1
Authority
WO
WIPO (PCT)
Prior art keywords
paper
tissue paper
tissue
propanediol
less
Prior art date
Application number
PCT/JP2016/088025
Other languages
French (fr)
Japanese (ja)
Inventor
秀太 保井
Original Assignee
大王製紙株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大王製紙株式会社 filed Critical 大王製紙株式会社
Publication of WO2017168877A1 publication Critical patent/WO2017168877A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47K—SANITARY EQUIPMENT NOT OTHERWISE PROVIDED FOR; TOILET ACCESSORIES
    • A47K7/00—Body washing or cleaning implements
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47K—SANITARY EQUIPMENT NOT OTHERWISE PROVIDED FOR; TOILET ACCESSORIES
    • A47K10/00—Body-drying implements; Toilet paper; Holders therefor
    • A47K10/16—Paper towels; Toilet paper; Holders therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a method for manufacturing a tissue paper product, and more particularly to a method for manufacturing a tissue paper product in which a bundle of tissue paper containing a humectant is stored in a storage container.
  • tissue paper product in which a bundle of a plurality of tissue papers is stored in a container such as a storage box and the tissue papers are sequentially pulled out from a take-out port provided on one side of the storage box and used is well known.
  • tissue paper products generally have a form called a pop-up type in which when one sheet is taken out, the next sheet is continuously drawn out from the outlet.
  • tissue paper product there is a drug-containing type in which a drug is contained in tissue paper.
  • tissue-type tissue paper has been improved in “softness” by the hygroscopic action of glycerin contained in the drug, and in particular, the user can realize that the nose does not hurt when biting the nose. .
  • interfolder a bundle of tissue paper stored in a storage box in such tissue paper products is formed by a folding device called an interfolder.
  • Interfolders are roughly classified into rotary interfolders and multi-stand interfolders depending on the folding method.
  • the rotary interfolder is relatively small and easy to switch between rolls, and has good folding quality such as sheet alignment, so it is suitable for production of high value-added products.
  • the rotary interfolder has an advantage that the medicine can be easily applied online in the apparatus. For this reason, bundles of tissue paper containing a drug are often manufactured by a rotary interfolder.
  • the main problem of the present invention is that the base paper for forming a bundle can be folded at a high speed, and it is excellent in “softness” and has a heavy load on the skin even if it is frequently used in the bite. It is an object of the present invention to provide a method for producing a drug-containing tissue paper which is a small amount of tissue paper.
  • tissue according to claim 1 wherein the basis weight of the tissue paper after applying the moisturizing liquid is 11.8 g / m 2 or more and 13.0 g / m 2 or less, and the paper thickness at 2 plies is 125 ⁇ m or more and 135 ⁇ m or less. Paper product manufacturing method.
  • tissue paper can be folded at a high speed to form a bundle, and is excellent in “softness” and has a low burden on the skin even if it is frequently used for squeezing.
  • a method for producing a tissue paper containing a drug is provided.
  • tissue paper product a bundle of tissue paper in which a plurality of tissue papers are folded and layered is stored in a storage box having an outlet or an outlet forming portion formed on the upper surface, and is used at the time of use.
  • a set of tissue paper is taken out from the take-out port, a part of the set of adjacent lower layers is exposed from the take-out port.
  • One set here refers to a cut sheet unit of tissue paper, and is composed of multiple layers of crepe paper.
  • the bundle of tissue paper according to the present embodiment is formed by folding and stacking tissue paper. More specifically, the rectangular tissue paper is substantially folded in half, and the folded pieces are stacked while being alternately overlapped so that the edges of the folded pieces are positioned on the folded inner surface of the tissue paper adjacent to the top and bottom.
  • the term “substantially” means that a slight fold of the edge formed in manufacturing is allowed.
  • tissue paper when one folded piece located at the uppermost position is pulled up, the other folded piece immediately below it is pulled upward by friction and lifted.
  • a bundle of tissue paper having such a structure is stored with its uppermost surface facing the upper surface of the storage box having an outlet or the like on the upper surface, and the first set (uppermost surface) from the outlet, particularly the slit. When one set) is pulled out, a part of the other set located immediately below is exposed.
  • the number of tissue papers in the present invention is not limited, but a typical number of sheets of this type of product is 120 to 240.
  • the tissue paper bundle is manufactured by a rotary interfolder.
  • the rotary interfolder 1 includes a pair of folding rolls called folding rolls 11, 11 and another one arranged as necessary, such as knife rolls 12, 12. It has the folding mechanism part 10 provided with a some roll. And each continuous strip
  • the bundle 30 is finally folded by the pair of folding rolls 11 and 11 and sequentially stacked to form a bundle 30.
  • tissue paper manufacturing method first, a pair of original rolls 20, 20 are rotatably attached to the original roll support part of the rotary interfolder 1, and the original rolls 20, 20 are used. Two-ply laminated tissue paper bases 21 and 21 are fed out.
  • the raw fabric rolls 20 and 20 are obtained by laminating two strip-shaped single-layer tissue paper base sheets and winding them up as two-ply laminated tissue paper base sheets by a ply machine of the former equipment.
  • single-layer tissue paper is manufactured at the papermaking equipment, which is the pre-equipment before the ply machine.
  • the steps from the papermaking raw material to making a two-ply laminated tissue paper base paper are not limited and can be performed by a known method.
  • the fiber material which comprises the tissue paper (tissue paper base paper) which concerns on this embodiment is a pulp fiber, and it is desirable that they are NBKP (conifer kraft pulp) and LBKP (hardwood kraft pulp) used for tissue paper.
  • NBKP conifer kraft pulp
  • LBKP hardwood kraft pulp
  • waste paper pulp may be blended, it is highly desirable that it is composed of only virgin pulp NBKP and LBKP.
  • the laminated tissue paper base paper 21 until the laminated tissue paper bases 21 and 21 fed from the raw rolls 20 and 20 are guided to the folding mechanism unit 10, A moisturizing liquid is applied to 21.
  • the moisturizing liquid to be applied is not mere glycerin, but characteristically glycerin and 1,3-propanediol as main components, and the glycerin and 1,3-propanediol
  • the mass ratio is more than 1: 0.03 and less than 1: 0.25.
  • the coating amount is set to 1.0 g / m 2 or more 2.2 g / m of less than 2 in the amount of active ingredient to the stacking tissue paper sheet.
  • the active ingredient means glycerin and 1,3-propanediol.
  • Conventionally commercially available moisturizing tissue paper has a drug content of about 4.5 to 7.5 g / m 2 .
  • the moisturizing liquid according to the present invention is very excellent in “soft” and “soft” even at such a low coating amount as described later, and also has “wet” and “wet”. It can be very little tissue paper.
  • the amount of application can be reduced by the above-described characteristic moisturizing chemical solution. Dirt, chemical adhesion, and paper dust are greatly suppressed.
  • 1,3-propanediol suppresses the “stickiness” and the like while reducing the “softness” due to the hygroscopic action of glycerin rather than reducing it, and it is a general-purpose type. Therefore, the slipperiness of the laminated tissue paper 21 and 21 after application of the moisturizing chemical solution in the rotary interfolder 1 is excellent, and from this point, it is possible to cope with high speed.
  • the moisturizing liquid according to the present invention contains glycerin and 1,3-propanediol as main components for expressing the effect as a moisturizing agent. More specifically, glycerin and 1,3-propanediol are used.
  • the total content of propanediol should be more than 67.9% by mass, preferably 69.9% by mass or more.
  • “softness” and “soft feeling” may not easily be exhibited at a low coating amount. That is, there is a high possibility that the high speed of the rotary interfolder cannot be achieved.
  • the moisturizing liquid according to the present invention may contain known auxiliaries in addition to glycerin and 1,3-propanediol as long as the effects of the present invention are not hindered.
  • auxiliaries include moisturizing auxiliary components such as sorbitol, hydrophilic polymer gelling agents such as glucomannan, and surfactants and phosphates, etc., to increase the retention of moisture in tissue paper.
  • moisturizers include improvers, oily components such as liquid paraffin that assist in the expression of smoothness, other emulsifiers, preservatives, antifoaming agents, etc., for improving the stability and stability of the moisturizer.
  • components such as a moisturizing auxiliary component and a hydrophilic polymer gelling agent that enhances moisture retention may reduce the effect of improving the “soft feeling” and the effect of suppressing the “wet feeling”. Therefore, it is good to set it as 1.0 mass% or less, Preferably it is 0.6 mass% or less, More preferably, it is 0.5 mass% or less.
  • the moisturizing liquid according to the present invention may be adjusted by adjusting glycerin, 1,3-propanediol and an appropriate auxiliary agent to a viscosity according to the coating method using an appropriate solvent such as water.
  • the method for producing tissue paper according to the present invention as a method for applying the moisturizing chemical solution to the laminated tissue paper base papers 21 and 21, roll transfer devices such as flexographic printing machines and gravure printing machines, spray coating devices, etc.
  • a coating method by external addition using a known chemical solution coating equipment can be employed.
  • a doctor chamber type flexographic printing machine 13, 13... Is installed on each side of the laminated tissue paper 21, 21, and moisturizing chemicals are applied from both sides. .
  • the moisturizing chemical solution according to the present invention is applied to the laminated tissue paper base paper 21 from both sides or from one side, homogenization proceeds between plies that come into contact during the subsequent seasoning period or product storage, The drug is homogenized throughout the two-ply tissue paper. Therefore, the moisturizing chemical solution may be applied to the tissue paper base from one side. However, if it is applied only from one side, there will be a difference in smoothness between the front and back before the moisturizing liquid penetrates, and there may be a difference in the running performance of the front and back in the interfolder. desirable.
  • the laminated tissue paper base paper 21 to which the moisturizing chemical solution is applied as described above is guided to the folding mechanism unit 10 according to the device structure and operation method of the rotary interfolder 1, It is formed in a bundle 30 of wide tissue paper substantially corresponding to the width of the original roll 20.
  • the folding method in the folding mechanism is not particularly limited.
  • the bundle is cut into a size suitable for each product and packed into a product.
  • the tissue paper according to the present invention preferably has a basis weight per ply of 11.8 g / m 2 or more and 13.0 g / m 2 or less, and a paper thickness at 2 plies of 125 ⁇ m or more and 135 ⁇ m or less.
  • the basis weight is a value measured based on JIS P 8124 (1998).
  • the paper thickness was adjusted sufficiently under the conditions of JIS P 8111 (1998), and then a dial thickness gauge (thickness measuring instrument) “PEACOCK G type” (manufactured by Ozaki Seisakusho) was used under the same conditions. The value measured in a 2-ply state.
  • the plunger when measuring the paper thickness, make sure that there is no dust, dust, etc. between the plunger and the measurement table, lower the plunger on the measurement table, and move the memory of the dial thickness gauge. Align the zero point, then raise the plunger and place the sample on the test bench, slowly lower the plunger and read the gauge at that time. At this time, only the plunger is placed.
  • the terminal of the plunger is made of metal so that a circular plane having a diameter of 10 mm is perpendicular to the plane of the paper, and the load at the time of measuring the paper thickness is about 70 gf.
  • the paper thickness is an average value obtained by performing measurement 10 times.
  • the tissue paper produced by the method for producing tissue paper according to the present invention has a mass ratio of glycerin to 1,3-propanediol of more than 1: 0.03 and 1: 0.25 at the basis weight and paper thickness described above. Less than 1.0 g / m 2 and 2.2 g / m 2 or less.
  • medical agent content here is the quantity of the chemical
  • the term “absolutely dry” refers to the amount of the drug in a state of being dried at a temperature of 65 ° C. and a humidity of 10% until reaching a constant weight.
  • the tissue paper according to the present invention is particularly excellent in “softness”, “smoothness”, and “softness”, and the feeling of drug application such as “wetness”, “moistness”, and “stickiness” is extremely reduced. Will be. When any one of the above-described configurations of the number of plies, basis weight, paper thickness, drug composition, and drug content is outside the range of the above numerical values, such a functional effect may be difficult to be exhibited. In addition, in the manufacturing method of the tissue paper which concerns on this invention, what is necessary is just to adjust the basic weight of tissue paper base paper, the crepe rate at the time of papermaking, the viscosity of a moisturizing chemical
  • the mass ratio of glycerin and 1,3-propanediol that is preferable from the viewpoint of functionality is 1: 0.04 or more and 1: 0.21 or less. Therefore, a preferred mass ratio of glycerin and 1,3-propanediol in the moisturizing liquid in the method for producing tissue paper according to the present invention is 1: 0.04 or more and 1: 0.21 or less.
  • the ratio of 1.3-propanediol in the paper is more than 0.13% by mass and less than 1.70% by mass from the viewpoint of functionality.
  • 1,3-propanediol reduces the “wetness”, “wetness” and “stickiness”, and the dryness and “smoothness” of the general-purpose type are more reliable. It becomes easy to express.
  • the tissue paper according to the present invention has a longitudinal elongation of 10.0% to 12.9%, preferably 10.0% to 12.1%.
  • the elongation rate is also related to the surface property of the tissue paper having a fine crepe on the surface.
  • this elongation rate means the value measured according to the tension test of JISP8113 (1998). Examples of the measuring apparatus include “Universal Tensile and Compression Tester TG-200N” manufactured by Minebea Co., Ltd. The elongation rate can be adjusted by the crepe rate at the time of paper making of the tissue paper.
  • the tissue paper according to the present invention has a dry tensile strength in the CD direction of 2 plies of 90 cN / 25 mm or more and 120 cN / 25 mm or less, preferably 92 cN / 25 mm or more and 116 cN / 25 mm or less.
  • the strength is 35 cN / 25 mm or more and 60 cN / 25 mm or less, preferably 40 cN / 25 mm or more and 53 cN / 25 mm or less, and the ratio of the wet tensile strength in the CD direction of 2 plies to the dry tensile strength in the CD direction of 2 plies is 0.40.
  • the above is desirable.
  • the CD direction is also called a paper lateral direction, and is a direction orthogonal to the flow direction (MD direction) during papermaking.
  • the dry tensile strength is defined in JIS P8113, and the wet tensile strength is defined in JIS P8135 (1998). With each of the above strengths, sufficient strength to withstand use can be exhibited, and the user can be provided with “sturdiness (strength / security)”.
  • the ratio of the wet tensile strength in the CD direction of the two plies to the dry tensile strength in the CD direction of the two plies is 0.40 or more, compared to a general moisturizing tissue,
  • the strength difference between dry and wet is relatively small.
  • Such a difference in strength makes it possible for the user to feel “sturdiness (strength / reassurance) in a usage mode that changes from dry to wet, especially when biting a heel.
  • the change in the strength of the paper in such a usage mode becomes difficult to be felt, and the sense of incongruity that the “smoothness” changes during use is not felt.
  • a dry paper strength enhancer or a wet paper strength enhancer can be internally added to the stock or wet paper.
  • the dry paper strength enhancer starch, polyacrylamide, CMC (carboxymethylcellulose) or a salt thereof such as sodium carboxymethylcellulose, carboxymethylcellulose calcium, carboxymethylcellulose zinc and the like can be used.
  • the wet paper strength enhancer polyamide polyamine epichlorohydrin resin, urea resin, acid colloid / melamine resin, thermally crosslinkable coating PAM, and the like can be used.
  • the amount added to the pulp slurry is about 1.0 kg / pulp t or less.
  • the wet paper strength enhancer is preferably a cationic one, and the amount added to the pulp slurry is about 5.0 to 20.0 kg / pulp t.
  • the MMD is less than 7.9 and the softness is less than 1.09 cN / 100 mm. Particularly preferably, the MMD is 7.7 or less and the softness is 1.03 cN / 100 mm or less.
  • MMD is one of the indices of “smoothness” of the surface, and if it is in the above range, the smoothness is felt sufficiently.
  • Softness is one of the indices of “softness”, and within the above range, it is easy to feel the difference in “softness” from a general-purpose tissue paper that does not contain a moisturizing agent. , Koshi will be felt.
  • the MMD and softness can be achieved by setting the number of plies, basis weight, paper thickness, drug composition, and drug content of the present invention. Further adjustments can be made by pulp composition and crepe rate during production.
  • MMD is the average deviation of the friction coefficient. The smaller the value, the smoother the value, and the larger the value, the less smooth.
  • the contact surface of the friction element is brought into contact with the surface of the measurement sample to which a tension of 20 g / cm is applied in a predetermined direction at a contact pressure of 25 g, and is substantially the same as the direction in which the tension is applied.
  • the friction coefficient at this time is measured using a friction tester KES-SE (manufactured by Kato Tech Co., Ltd.).
  • the value obtained by dividing the friction coefficient by the friction distance 2 cm) is MMD.
  • the friction element has 20 piano wires P having a diameter of 0.5 mm adjacent to each other, and has a contact surface formed so that the length and the width are both 10 mm.
  • the contact surface is assumed to have a unit bulge portion formed with 20 piano wires P (curvature radius 0.25 mm) at the tip.
  • Softness is a value measured according to the handle ohm method according to JIS L 1096 E method. However, the test piece is 100 mm ⁇ 100 mm in size, and the clearance is 5 mm. The measurement is performed 5 times each in the longitudinal direction and the lateral direction with 1 ply, and the average value of all 10 times is expressed in units of cN / 100 mm.
  • tissue paper according to the present embodiment described above is a low coating amount, it is excellent in its “softness”, “soft feeling”, “wet feeling / moist feeling”, and “ This will be described with reference to “Examples”.
  • the density is a value obtained by dividing a value (C) obtained by doubling the basis weight of tissue paper conditioned under the conditions of JIS P 8111 (1998) by the paper thickness (D) of the above-described tissue paper (2 plies).
  • the unit is g / cm 3 , and the decimal point is 3 digits.
  • the drug content is the amount of drug in the sample when absolutely dry.
  • the time of absolute dry is the quantity of the chemical
  • the drug content is the ratio of the drug contained in the sample at the absolute dryness.
  • the drug content (including water) is the ratio of the drug (including water) contained in the sample in a condition of being conditioned for 24 hours under conditions of a temperature of 23 ° C. and a humidity of 50%.
  • the amount of the drug is calculated from the mass of the sample in a conditioned state, the mass of the sample when absolutely dry, and the drug content.
  • the ratio of 1,3-propanediol in paper is the ratio of the mass of 1,3-propanediol to the mass of the sample when absolutely dry.
  • “Comprehensive evaluation” is “5” for those who feel “good touch and very high intention to purchase”, “4” for those who feel “good touch and high intention to purchase”, “ “3” for those who feel that the touch is normal, and that the purchase intention is high or low can be said to be “3”; for those that feel that “the touch is poor and the purchase intention is low”, “2”, “the touch is very Those who felt that they were inferior and almost not intending to purchase were evaluated as “1”, and the average score of each evaluator was calculated as the evaluation value.
  • the comparative example 3 is corresponded to the base paper before giving the chemical
  • Test results will be described with reference to FIG. 2 in which the sensory evaluations in Examples 1 to 7 and Comparative Examples 3 to 8 shown in Table 1 and Table 1 are graphed.
  • the horizontal axis corresponds to the drug content of 1,3-propanediol
  • the vertical axis corresponds to sensory evaluation.
  • Each sample in Table 1 is a non-moisturizing tissue paper in which Comparative Examples 1 to 3 do not contain a moisturizing agent, and these differ in basis weight and paper thickness.
  • the basis weight and paper thickness decrease, the “wetness / moistness” improves, but the “softness” and “softness” tend to decrease. , Low willingness to buy.
  • Comparative Example 4 contains 1.0 g / m 2 of a drug mainly containing conventional glycerin not containing 1,3-propanediol, that is, a drug having a 1,3-propanediol ratio of 0. Is. Comparative Example 4 has the drug content as low as that of Examples 1 and 2 while using only conventional glycerin as the main effective ingredient. When this Comparative Example 4 is compared with Comparative Example 3 which is a reference sample, the “wet feeling / moist feeling” does not decrease due to the low drug content. In addition, “softness” is slightly improved. However, it can be confirmed that the “soft feeling” is slightly reduced in exchange.
  • Comparative Example 5 and Comparative Example 6 have the same drug content as Comparative Example 4, but use a drug containing glycerin and 1,3-propanediol. However, the mass ratio of glycerin and 1,3-propanediol is different from that of the present invention, and the ratio of 1.3 propanediol is particularly lower than that of the present invention. In Comparative Examples 5 and 6, Comparative Example 6 has a higher ratio of 1,3-propanediol. Comparing Comparative Example 4 to Comparative Example 6, “softness” improves as the ratio of 1,3-propanediol in the paper increases, and “softness” also increases as the ratio increases. ing. "Wet feeling and wet feeling" has not decreased.
  • Example 1 is “soft” despite the same drug content as Comparative Examples 4 to 6. Significant improvements can be confirmed in “sa” and “soft”. It can be confirmed that overall evaluation (motivation to purchase) is also increasing.
  • Example 1 to Example 11 The drug content increases from Example 1 to Example 11.
  • Example 6 and Example 7, Example 10 and Example 11 respectively have the same drug content.
  • Example 9 As they go from Example 1 to Example 2, Example 3, Example 4, and Example 5, “softness”, “softness”, “wetness / wetness” ”And the evaluation is very high from Example 5 to Example 8. From Example 9, there is a tendency for the evaluation to decrease slightly.
  • the overall evaluation (motivation to purchase) also peaks in Examples 5 to 8. In Examples 1 to 11, sufficiently satisfactory results were obtained for MMD and softness.
  • Comparative Example 7 has a higher proportion of 1,3-propanediol than Example 11 and is outside the scope of the present invention. It is what has become. Comparative Example 8 has a higher proportion of 1,3-propanediol than Comparative Example 7. Comparing these, Comparative Example 7 is “softer” than Examples 10 to 11 despite the sufficient amount of glycerin and the high proportion of 1,3-propanediol. The drop in the evaluation of “sa” and “softness” is severe. The evaluation of “wetness / moistness” has also fallen sharply. Further, in Comparative Example 11, the drug content and the proportion of 1,3-propanediol are higher than those in Comparative Example 7, but in Comparative Example 8, the evaluations of “softness” and “soft feeling” drop sharply. ing.
  • Comparative Example 9 contains 2.6 g / m 2 of a drug containing, as a main effective ingredient, only conventional glycerin that does not contain 1,3-propanediol, and Comparative Example 10 mainly contains only conventional glycerin.
  • the drug as an effective ingredient contains 6.3 g / m 2 .
  • “softness” is higher in evaluation than Comparative Example 3 as a reference sample, “soft feeling” is equivalent, and “wet feeling / moist feeling” is low in evaluation.
  • the comparative example 10 is low in all evaluation items.
  • Comparative Example 9 has a slightly lower drug content than that of a conventional commercial product, but is higher than that of Comparative Example 4, that is, “softness”, “ It is shown that it is impossible to achieve both “feel” and “stickiness”.
  • the comparative example 10 is a chemical

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Sanitary Thin Papers (AREA)
  • Cosmetics (AREA)
  • Paper (AREA)

Abstract

[Problem] To increase the producibility of tissue-paper coated with a liquid chemical. [Solution] The problem is overcome by a method for manufacturing a tissue-paper product having a step in which a 2-ply layered tissue-paper base paper, on which tissue-paper base paper in band form is layered, is coated in a rotary interfolder with a liquid chemical in an amount of at least 1.0 g/m2 to less than 2.2 g/m2 in terms of the active component content, said liquid chemical principally comprising glycerin and 1,3-propanediol, and the mass ratio of glycerin and 1,3-propanediol is 1:0.03 to 1:0.25 exclusive.

Description

ティシュペーパー製品の製造方法Manufacturing method of tissue paper products
　本発明は、ティシュペーパー製品の製造方法に関し、特に、保湿剤を含むティシュペーパーの束が収納容器に収納されているティシュペーパー製品の製造方法に関する。 The present invention relates to a method for manufacturing a tissue paper product, and more particularly to a method for manufacturing a tissue paper product in which a bundle of tissue paper containing a humectant is stored in a storage container.
　複数枚のティシュペーパーからなる束が収納箱等の容器に収納され、その収納箱の一面に設けられた取り出し口からティシュペーパーを順次一枚ずつ引き出して使用するティシュペーパー製品はよく知られる。このようなティシュペーパー製品は、一枚を取り出すとそれに連続して次ぎの一枚が取出し口から引き出されるポップアップ式と言われる形態が一般的である。 A tissue paper product in which a bundle of a plurality of tissue papers is stored in a container such as a storage box and the tissue papers are sequentially pulled out from a take-out port provided on one side of the storage box and used is well known. Such tissue paper products generally have a form called a pop-up type in which when one sheet is taken out, the next sheet is continuously drawn out from the outlet.
　このティシュペーパー製品においては、ティシュペーパーに薬剤が含有されている薬剤含有タイプのものがある。従来、薬剤含有タイプのティシュペーパーは、薬剤中に含まれるグリセリンの吸湿作用によって「柔らかさ」が高められ、特に、使用者は鼻を繰り返しかんだ際に、鼻周りが痛くならないことが、実感できる。 In this tissue paper product, there is a drug-containing type in which a drug is contained in tissue paper. Conventionally, tissue-type tissue paper has been improved in “softness” by the hygroscopic action of glycerin contained in the drug, and in particular, the user can realize that the nose does not hurt when biting the nose. .
　一方、このようなティシュペーパー製品において収納箱内に収められるティシュペーパーの束は、インターフォルダといわれる折り畳み装置によって形成される。インターフォルダには、折り畳み方式の相違によって、ロータリー式インターフォルダとマルチスタンド式インターフォルダとに大別される。 On the other hand, a bundle of tissue paper stored in a storage box in such tissue paper products is formed by a folding device called an interfolder. Interfolders are roughly classified into rotary interfolders and multi-stand interfolders depending on the folding method.
　なかでもロータリー式インターフォルダは比較的小型でロールの切り替えが容易であり、またシートの揃いなどの折り品質が良いことから、高付加価値商品の生産に向いている。また、ロータリー式インターフォルダは、装置内において薬剤をオンライン塗布しやすい利点がある。このため、薬剤が含有されたティシュペーパーの束は、ロータリー式インターフォルダで製造されることが多い。 Among them, the rotary interfolder is relatively small and easy to switch between rolls, and has good folding quality such as sheet alignment, so it is suitable for production of high value-added products. In addition, the rotary interfolder has an advantage that the medicine can be easily applied online in the apparatus. For this reason, bundles of tissue paper containing a drug are often manufactured by a rotary interfolder.
　しかしながら、近年、生産性を高めるべく、ロータリー式インターフォルダの高速化が進んでおり、この高速化によって、薬剤を含有したティシュペーパーを製造する場合に、薬液が飛散して装置へ薬液や汚れが付着したり、紙粉が発生したりする問題が生ずるようになってきた。また、グリセリンを主成分とする薬剤が含有されている原紙はすべりやすいため、高速化によって折り不良や皺も発生しやすくなるため、品質の低下や断紙のおそれも高まる。そして、このような問題を改善すべく、薬剤の含有量を少なくすると、従来薬剤では「柔らかさ」が低下し、保湿ティシュペーパーとしての品質が担保されない。 However, in recent years, in order to increase productivity, the speed of rotary type interfolders has been increased. With this speed increase, when manufacturing tissue paper containing chemicals, chemicals are scattered and chemicals and dirt are left on the device. There has been a problem of adhesion and generation of paper dust. In addition, since a base paper containing a drug containing glycerin as a main component is easy to slip, folding failure and wrinkles are likely to occur due to high speed, and the risk of quality deterioration and paper breakage increases. And if content of a chemical | medical agent is decreased in order to improve such a problem, with a conventional chemical | medical agent, "softness" will fall and the quality as moisture retention tissue paper will not be ensured.
特表２０１３－５１１５０９号公報Special table 2013-511509 gazette 特表２０１３－５１１５０８号公報Special table 2013-511508 gazette 特表２０１１－５２２１３３号公報Special table 2011-522133 gazette
　そこで、本発明の主たる課題は、束を形成するための原紙の折り畳みを高速に行なうことができ、しかも、「柔らかさ」に優れ、洟かみに頻繁に使用するなどしても肌に対する負荷が少ないティシュペーパーとなる、薬剤含有のティシュペーパーの製造方法を提供することにある。 Therefore, the main problem of the present invention is that the base paper for forming a bundle can be folded at a high speed, and it is excellent in “softness” and has a heavy load on the skin even if it is frequently used in the bite. It is an object of the present invention to provide a method for producing a drug-containing tissue paper which is a small amount of tissue paper.
　上記課題を解決するための手段及びそれらの作用効果は次記のとおりである。
〔請求項１記載の発明〕
　ロータリー式インターフォルダにおいて、帯状のティシュペーパー原紙を積層した２プライの積層ティシュペーパー原紙に対して、
　グリセリンと１，３－プロパンジオールを主成分とし、グリセリンと１，３－プロパンジオールの質量比が１：０．０３超１：０．２５未満である保湿薬液を、有効成分量で１．０ｇ／ｍ2以上２．２ｇ／ｍ2未満塗布する工程を有する、ことを特徴とするティシュペーパー製品の製造方法。 Means for solving the above problems and their effects are as follows.
[Invention of Claim 1]
In the rotary type interfolder, for the two-ply laminated tissue paper base paper, which is a stack of belt-shaped tissue paper base paper,
1.0 g of a moisturizing liquid containing glycerin and 1,3-propanediol as main components and having a mass ratio of glycerin to 1,3-propanediol of more than 1: 0.03 and less than 1: 0.25 in an amount of active ingredients. / m with two or more 2.2 g / m 2 less coating to method of manufacturing an tissue paper product characterized in that.
〔請求項２記載の発明〕
　保湿薬液を塗布した後のティシュペーパー原紙の坪量を、１１．８ｇ／ｍ2以上１３．０ｇ／ｍ2以下、２プライでの紙厚を１２５μｍ以上１３５μｍ以下とする、請求項１記載のティシュペーパー製品の製造方法。 [Invention of Claim 2]
The tissue according to claim 1, wherein the basis weight of the tissue paper after applying the moisturizing liquid is 11.8 g / m 2 or more and 13.0 g / m 2 or less, and the paper thickness at 2 plies is 125 µm or more and 135 µm or less. Paper product manufacturing method.
　本発明によれば、束を形成するための原紙の折り畳みを高速に行なうことができ、しかも、「柔らかさ」に優れ、洟かみに頻繁に使用するなどしても肌に対する負荷が少ないティシュペーパーとなる、薬剤含有のティシュペーパーの製造方法が提供される。 According to the present invention, tissue paper can be folded at a high speed to form a bundle, and is excellent in “softness” and has a low burden on the skin even if it is frequently used for squeezing. A method for producing a tissue paper containing a drug is provided.
本発明の製造方法を説明するための概略図である。It is the schematic for demonstrating the manufacturing method of this invention. 実施形態に係る試験例の結果を示すグラフである。It is a graph which shows the result of the example of a test concerning an embodiment.
　以下、本発明の実施形態を説明する。 Hereinafter, embodiments of the present invention will be described.
　本実施形態に係るティシュペーパー製品は、複数枚のティシュペーパーが、折り畳まれ重層されてなるティシュペーパーの束が、上面に取出口又は取出口形成部が形成された収納箱に収納され、使用時にこの取出口からティシュペーパーの一組を取り出すと、隣接して積層されている下層の一組の一部が取出口から露出されるように構成されたものである。ここでいう一組とは、ティシュペーパーのカットシート単位をいい、複層のクレープ紙からなる。 In the tissue paper product according to this embodiment, a bundle of tissue paper in which a plurality of tissue papers are folded and layered is stored in a storage box having an outlet or an outlet forming portion formed on the upper surface, and is used at the time of use. When a set of tissue paper is taken out from the take-out port, a part of the set of adjacent lower layers is exposed from the take-out port. One set here refers to a cut sheet unit of tissue paper, and is composed of multiple layers of crepe paper.
　また、本実施形態に係るティシュペーパーの束は、ティシュペーパーが折り畳まれ、積層されてなるものである。より具体的には、方形のティシュペーパーが実質的に二つ折りされ、その折り返し片の縁が上下に隣接するティシュペーパーの折り返し内面に位置するようにして、互い違いに重なり合いつつ積層されている。なお、ここで実質的にとは、製造上の形成される縁部の若干の折り返しを許容する意味である。 In addition, the bundle of tissue paper according to the present embodiment is formed by folding and stacking tissue paper. More specifically, the rectangular tissue paper is substantially folded in half, and the folded pieces are stacked while being alternately overlapped so that the edges of the folded pieces are positioned on the folded inner surface of the tissue paper adjacent to the top and bottom. Here, the term “substantially” means that a slight fold of the edge formed in manufacturing is allowed.
　この積層構造のティシュペーパーの束は、最上位に位置する一枚の折り返し片を上方に引き上げると、その直下で隣接する他の一枚の折り返し片が、摩擦により上方に引きずられて持ち上げられる。そして、かかる構造のティシュペーパーの束は、その最上面が上述の上面に取出口等を有する収納箱の当該上面に向かいあって収納され、前記取出口、特にスリットから最初の一組（最上面に位置する一組）が引き出されたときに、その直近下方に位置する他の一組の一部が露出される。なお、本発明のおけるティシュペーパーの積層枚数が限定されないが、この種の製品の一般的な積層枚数を例示すれば、１２０～２４０組である。 In this stack of tissue paper, when one folded piece located at the uppermost position is pulled up, the other folded piece immediately below it is pulled upward by friction and lifted. A bundle of tissue paper having such a structure is stored with its uppermost surface facing the upper surface of the storage box having an outlet or the like on the upper surface, and the first set (uppermost surface) from the outlet, particularly the slit. When one set) is pulled out, a part of the other set located immediately below is exposed. Note that the number of tissue papers in the present invention is not limited, but a typical number of sheets of this type of product is 120 to 240.
　本発明に係るティシュペーパーの製造方法では、このティシュペーパーの束をロータリー式インターフォルダで製造する。図１に示すように、本発明に係るロータリー式インターフォルダ１は、フォールディングロール１１，１１と呼ばれる一対の折ロールと、ナイフロール１２，１２等の必要に応じて配される他の一つ又は複数のロールとを備える折畳み機構部１０を有するものである。そして、一対の原反ロール２０，２０から繰り出された各々連続する帯状の積層ティシュペーパー原紙２１，２１が搬送されて、折り畳み機構部１０に導かれ、その先端側が前記ナイフロール１１，１１等によって裁断された後に、最終的に一対のフォールディングロール１１，１１にて折り畳まれるとともに順次重ね合わせられて束３０が形成される。 In the tissue paper manufacturing method according to the present invention, the tissue paper bundle is manufactured by a rotary interfolder. As shown in FIG. 1, the rotary interfolder 1 according to the present invention includes a pair of folding rolls called folding rolls 11, 11 and another one arranged as necessary, such as knife rolls 12, 12. It has the folding mechanism part 10 provided with a some roll. And each continuous strip | belt-shaped lamination | stacking tissue paper base 21 and 21 drawn | fed out from a pair of original fabric rolls 20 and 20 are conveyed, and are guide | induced to the folding mechanism part 10, The front end side is by said knife rolls 11 and 11 grade | etc.,. After being cut, the bundle 30 is finally folded by the pair of folding rolls 11 and 11 and sequentially stacked to form a bundle 30.
　本実施形態に係るティシュペーパーの製造方法では、まず、そのロータリー式インターフォルダ１の原反ロール支持部に一対の原反ロール２０，２０を回動自在に取付け、この原反ロール２０，２０から２プライの積層ティシュペーパー原紙２１，２１を繰出す。原反ロール２０，２０は、前段設備のプライマシンで、帯状の単層のティシュペーパー原紙を二枚積層して２プライの積層ティシュペーパー原紙として巻き取ったものである。 In the tissue paper manufacturing method according to the present embodiment, first, a pair of original rolls 20, 20 are rotatably attached to the original roll support part of the rotary interfolder 1, and the original rolls 20, 20 are used. Two-ply laminated tissue paper bases 21 and 21 are fed out. The raw fabric rolls 20 and 20 are obtained by laminating two strip-shaped single-layer tissue paper base sheets and winding them up as two-ply laminated tissue paper base sheets by a ply machine of the former equipment.
　なお、単層のティシュペーパー原紙は、プライマシンよりさらに前段設備の抄紙設備にて製造する。本発明に係るティシュペーパーの製造方法では、抄紙原料から２プライの積層ティシュペーパー原紙とするまでの工程については、限定されることなく、公知の方法によることができる。 In addition, single-layer tissue paper is manufactured at the papermaking equipment, which is the pre-equipment before the ply machine. In the method for producing tissue paper according to the present invention, the steps from the papermaking raw material to making a two-ply laminated tissue paper base paper are not limited and can be performed by a known method.
　なお、本実施形態に係るティシュペーパー（ティシュペーパー原紙）を構成する繊維素材は、パルプ繊維であり、ティシュペーパーに用いられるＮＢＫＰ（針葉樹クラフトパルプ）及びＬＢＫＰ（広葉樹クラフトパルプ）であるのが望ましい。古紙パルプが配合されていてもよいが、バージンパルプのＮＢＫＰとＬＢＫＰのみから構成されているのが極めて望ましい。配合割合としては、質量比でＮＢＫＰ：ＬＢＫＰ＝２５：７５～４０：６０である。 In addition, the fiber material which comprises the tissue paper (tissue paper base paper) which concerns on this embodiment is a pulp fiber, and it is desirable that they are NBKP (conifer kraft pulp) and LBKP (hardwood kraft pulp) used for tissue paper. Although waste paper pulp may be blended, it is highly desirable that it is composed of only virgin pulp NBKP and LBKP. The mixing ratio is NBKP: LBKP = 25: 75 to 40:60 by mass ratio.
　他方、本実施形態に係るティシュペーパーの製造方法では、原反ロール２０，２０から繰出された積層ティシュペーパー原紙２１，２１が折り畳み機構部１０に導かれるまでの間において、積層ティシュペーパー原紙２１，２１に対して保湿薬液を塗布する。 On the other hand, in the tissue paper manufacturing method according to the present embodiment, the laminated tissue paper base paper 21, until the laminated tissue paper bases 21 and 21 fed from the raw rolls 20 and 20 are guided to the folding mechanism unit 10, A moisturizing liquid is applied to 21.
　本実施形態に係るティシュペーパーの製造方法では、その塗布する保湿薬液を、単なるグリセリンではなく、特徴的にグリセリンと１，３－プロパンジオールを主成分とし、そのグリセリンと１，３－プロパンジオールの質量比が１：０．０３超１：０．２５未満のものとする。さらに、その塗布量は、積層ティシュペーパー原紙に対して有効成分量で１．０ｇ／ｍ2以上２．２ｇ／ｍ2未満とする。なお、有効成分とは、グリセリンと１，３－プロパンジオールを意味する。 In the method for producing tissue paper according to the present embodiment, the moisturizing liquid to be applied is not mere glycerin, but characteristically glycerin and 1,3-propanediol as main components, and the glycerin and 1,3-propanediol The mass ratio is more than 1: 0.03 and less than 1: 0.25. Further, the coating amount is set to 1.0 g / m 2 or more 2.2 g / m of less than 2 in the amount of active ingredient to the stacking tissue paper sheet. The active ingredient means glycerin and 1,3-propanediol.
　従来市販の保湿ティシュペーパーの薬剤含有量は、概ね４．５～７．５ｇ／ｍ2程度である。本発明に係るティシュペーパーの製造方法では、上記の通り保湿薬液の塗布量が有効成分量で１．０ｇ／ｍ2以上２．２ｇ／ｍ2未満であり非常に少ない。 Conventionally commercially available moisturizing tissue paper has a drug content of about 4.5 to 7.5 g / m 2 . In the method for producing tissue paper according to the present invention, very small less than 1.0 g / m 2 or more 2.2 g / m 2 in coated amount effective component amount of as moisturizing chemical above.
　そして、この本発明に係る保湿薬液は、後述するようにこのような低塗布量であっても「柔らかさ」、「ふんわり感」に非常に優れ、しかも「ウェット感」、「湿り感」が非常に少ないティシュペーパーとすることができる。 The moisturizing liquid according to the present invention is very excellent in “soft” and “soft” even at such a low coating amount as described later, and also has “wet” and “wet”. It can be very little tissue paper.
　すなわち、本発明に係るティシュペーパーの製造方法では、上記の特徴的な保湿薬液によって低塗布量とすることができるゆえ、ロータリー式インターフォルダ１を高速化しても薬液の飛散やそれによる装置への汚れや薬剤付着、紙粉の発生が格段に抑制される。また、本実施形態に係る薬剤では、１，３－プロパンジオールがグリセリンの吸湿作用による「柔らかさ」を低下させずむしろ向上させつつも、「べたつき感」等を抑え、汎用タイプのようなさらっとした表面性となり、過度に滑り性が高まらず、ロータリー式インターフォルダ１における保湿薬液塗布後の積層ティシュペーパー原紙２１，２１の走行性に優れ、この点からも高速化に対応できる。 That is, in the tissue paper manufacturing method according to the present invention, the amount of application can be reduced by the above-described characteristic moisturizing chemical solution. Dirt, chemical adhesion, and paper dust are greatly suppressed. In addition, in the drug according to this embodiment, 1,3-propanediol suppresses the “stickiness” and the like while reducing the “softness” due to the hygroscopic action of glycerin rather than reducing it, and it is a general-purpose type. Therefore, the slipperiness of the laminated tissue paper 21 and 21 after application of the moisturizing chemical solution in the rotary interfolder 1 is excellent, and from this point, it is possible to cope with high speed.
　ここで、本発明に係る上記保湿薬液は、グリセリンと１，３－プロパンジオールとを保湿剤としての効果発現の主成分とするものであるが、より具体的には、グリセリンと１，３－プロパンジオールとを合わせて６７．９質量％を超えて含むのがよく、好ましくは６９．９質量％以上含むものであるのがよい。保湿薬液中におけるグリセリンと１，３－プロパンジオールの総量が６７．９質量％以下であると、低塗布量において「柔らかさ」、「ふんわり感」が発現し難い場合がある。つまり、ロータリー式インターフォルダの高速化を達成できないおそれが高まる。 Here, the moisturizing liquid according to the present invention contains glycerin and 1,3-propanediol as main components for expressing the effect as a moisturizing agent. More specifically, glycerin and 1,3-propanediol are used. The total content of propanediol should be more than 67.9% by mass, preferably 69.9% by mass or more. When the total amount of glycerin and 1,3-propanediol in the moisturizing liquid is 67.9% by mass or less, “softness” and “soft feeling” may not easily be exhibited at a low coating amount. That is, there is a high possibility that the high speed of the rotary interfolder cannot be achieved.
　なお、本発明に係る保湿薬液中には、本発明の効果を妨げない範囲で、グリセリンと１，３－プロパンジオール以外に公知の助剤が含有されてもよい。助剤の例としては、ソルビトール等の保湿補助成分、ティシュペーパー中の水分の保持性を高めるための、グルコマンナン等の親水性高分子ゲル化剤、界面活性剤やリン酸エステル等の柔軟性向上剤、滑らかさの発現を補助する流動パラフィンなどの油性成分、その他、保湿剤の安定化、塗布性を向上させるための乳化剤、防腐剤、消泡剤等が挙げられる。なお、保湿補助成分、水分の保持性を高める親水性高分子ゲル化剤等の成分は、過度に含有させると「ふんわり感」の向上効果、「ウェット感」の抑制効果を低下させることがあるため、１．０質量％以下、好ましくは０．６質量％以下、より好ましくは０．５質量％以下とするのがよい。 The moisturizing liquid according to the present invention may contain known auxiliaries in addition to glycerin and 1,3-propanediol as long as the effects of the present invention are not hindered. Examples of auxiliaries include moisturizing auxiliary components such as sorbitol, hydrophilic polymer gelling agents such as glucomannan, and surfactants and phosphates, etc., to increase the retention of moisture in tissue paper. Examples include improvers, oily components such as liquid paraffin that assist in the expression of smoothness, other emulsifiers, preservatives, antifoaming agents, etc., for improving the stability and stability of the moisturizer. In addition, components such as a moisturizing auxiliary component and a hydrophilic polymer gelling agent that enhances moisture retention may reduce the effect of improving the “soft feeling” and the effect of suppressing the “wet feeling”. Therefore, it is good to set it as 1.0 mass% or less, Preferably it is 0.6 mass% or less, More preferably, it is 0.5 mass% or less.
　なお、本発明に係る保湿薬液の調整は、グリセリン、１，３－プロパンジオール及び適宜の助剤を、水などの適宜の溶媒を用い、塗布方法に応じた粘度に調整すればよい。 The moisturizing liquid according to the present invention may be adjusted by adjusting glycerin, 1,3-propanediol and an appropriate auxiliary agent to a viscosity according to the coating method using an appropriate solvent such as water.
　他方、本発明に係るティシュペーパーの製造方法において、上記の保湿薬液を積層ティシュペーパー原紙２１，２１に付与するに方法としては、フレキソ印刷機、グラビア印刷機等のロール転写装置、スプレー塗布装置など公知の薬液塗布設備を用いた、外添による塗布方法が採用できる。図１の形態では、好適な例として、積層ティシュペーパー原紙２１，２１の各面側にドクターチャンバー形式のフレキソ印刷機１３，１３…を設置して、両面から保湿薬液を付与するようにしている。なお、本発明に係る保湿薬液は、積層ティシュペーパー原紙２１に対して両面から付与しても片面から付与しても、その後のシーズニング期間や製品保管時において接するプライ間において均質化が進むため、２プライのティシュペーパー全体として薬剤が均質化される。したがって、ティシュペーパー原紙に対する保湿薬液の付与は、一方面から行なってもよい。ただし、一方面からのみ付与すると保湿薬液が浸透するまでに表裏面において滑らかさに差が生じ、インターフォルダ内での表裏面の走行性に差が生ずるおそれもあるから、両面塗布とするのが望ましい。 On the other hand, in the method for producing tissue paper according to the present invention, as a method for applying the moisturizing chemical solution to the laminated tissue paper base papers 21 and 21, roll transfer devices such as flexographic printing machines and gravure printing machines, spray coating devices, etc. A coating method by external addition using a known chemical solution coating equipment can be employed. In the form of FIG. 1, as a suitable example, a doctor chamber type flexographic printing machine 13, 13... Is installed on each side of the laminated tissue paper 21, 21, and moisturizing chemicals are applied from both sides. . In addition, since the moisturizing chemical solution according to the present invention is applied to the laminated tissue paper base paper 21 from both sides or from one side, homogenization proceeds between plies that come into contact during the subsequent seasoning period or product storage, The drug is homogenized throughout the two-ply tissue paper. Therefore, the moisturizing chemical solution may be applied to the tissue paper base from one side. However, if it is applied only from one side, there will be a difference in smoothness between the front and back before the moisturizing liquid penetrates, and there may be a difference in the running performance of the front and back in the interfolder. desirable.
　本発明に係るティシュペーパーの製造方法では、上記のように保湿薬液を付与した積層ティシュペーパー原紙２１は、ロータリー式インターフォルダ１の装置構造及び運転方法にしたがって、折り畳み機構部１０に導かれて、原反ロール２０の幅にほぼ対応する幅広のティシュペーパーの束３０に形成される。本発明においては、この折り畳み機構部における折り畳み方法は、特に限定されるものではない。 In the tissue paper manufacturing method according to the present invention, the laminated tissue paper base paper 21 to which the moisturizing chemical solution is applied as described above is guided to the folding mechanism unit 10 according to the device structure and operation method of the rotary interfolder 1, It is formed in a bundle 30 of wide tissue paper substantially corresponding to the width of the original roll 20. In the present invention, the folding method in the folding mechanism is not particularly limited.
　そして、本発明に係るティシュペーパーの製造方法では、幅広の束を形成した後には、公知の方法にしたがって、この束を個々の製品に適した大きさに裁断し、箱詰めして製品とする。 In the tissue paper manufacturing method according to the present invention, after forming a wide bundle, according to a known method, the bundle is cut into a size suitable for each product and packed into a product.
　以下、さらに本発明に係るティシュペーパーの製造方法によって製造されるティシュペーパーの好適例を示す。本発明に係るティシュペーパーは、１プライ当たりの坪量が１１．８ｇ／ｍ2以上１３．０ｇ／ｍ2以下、２プライでの紙厚が１２５μｍ以上１３５μｍ以下であるのが望ましい。坪量は、ＪＩＳ　Ｐ　８１２４（１９９８）に基づいて測定した値とする。また、紙厚は、試験片をＪＩＳ Ｐ ８１１１（１９９８）の条件下で十分に調湿した後、同条件下でダイヤルシックネスゲージ（厚み測定器）「ＰＥＡＣＯＣＫ Ｇ型」（尾崎製作所製）を用いて２プライの状態で測定した値とする。紙厚の測定は、具体的には、プランジャーと測定台の間にゴミ、チリ等がないことを確認してプランジャーを測定台の上におろし、前記ダイヤルシックネスゲージのメモリを移動させてゼロ点を合わせ、次いで、プランジャーを上げて試料を試験台の上におき、プランジャーをゆっくりと下ろしそのときのゲージを読み取る。このとき、プランジャーをのせるだけとする。プランジャーの端子は金属製で直径１０ｍｍの円形の平面が紙平面に対し垂直に当たるようにし、この紙厚測定時の荷重は、約７０ｇｆである。なお、紙厚は測定を１０回行って得られる平均値とする。 Hereinafter, the suitable example of the tissue paper manufactured by the manufacturing method of the tissue paper which concerns on this invention further is shown. The tissue paper according to the present invention preferably has a basis weight per ply of 11.8 g / m 2 or more and 13.0 g / m 2 or less, and a paper thickness at 2 plies of 125 μm or more and 135 μm or less. The basis weight is a value measured based on JIS P 8124 (1998). The paper thickness was adjusted sufficiently under the conditions of JIS P 8111 (1998), and then a dial thickness gauge (thickness measuring instrument) “PEACOCK G type” (manufactured by Ozaki Seisakusho) was used under the same conditions. The value measured in a 2-ply state. Specifically, when measuring the paper thickness, make sure that there is no dust, dust, etc. between the plunger and the measurement table, lower the plunger on the measurement table, and move the memory of the dial thickness gauge. Align the zero point, then raise the plunger and place the sample on the test bench, slowly lower the plunger and read the gauge at that time. At this time, only the plunger is placed. The terminal of the plunger is made of metal so that a circular plane having a diameter of 10 mm is perpendicular to the plane of the paper, and the load at the time of measuring the paper thickness is about 70 gf. The paper thickness is an average value obtained by performing measurement 10 times.
　つまり、本発明に係るティシュペーパーの製造方法によって製造するティシュペーパーは、上記の坪量及び紙厚において、グリセリンと１，３－プロパンジオールの質量比が１：０．０３超１：０．２５未満である薬剤を、１．０ｇ／ｍ2以上２．２ｇ／ｍ2以下含有するものである。なお、ここでの薬剤含有量は、絶乾時のティシュペーパーに含まれる薬剤の量であり、有効成分の塗布量とほぼ同様となる。ここで絶乾時とは、温度６５℃、湿度１０％で恒量となるまで乾燥させた状態における薬剤の量である。 That is, the tissue paper produced by the method for producing tissue paper according to the present invention has a mass ratio of glycerin to 1,3-propanediol of more than 1: 0.03 and 1: 0.25 at the basis weight and paper thickness described above. Less than 1.0 g / m 2 and 2.2 g / m 2 or less. In addition, the chemical | medical agent content here is the quantity of the chemical | medical agent contained in the tissue paper at the time of absolutely dry, and becomes substantially the same as the application amount of an active ingredient. Here, the term “absolutely dry” refers to the amount of the drug in a state of being dried at a temperature of 65 ° C. and a humidity of 10% until reaching a constant weight.
　この本発明に係るティシュペーパーは、特に「柔らかさ」、「滑らかさ」、「ふんわり感」に優れ、さらに「ウェット感」、「湿り感」、「ベタツキ感」といった薬剤塗布感が極めて低減されるものとなる。上記プライ数、坪量、紙厚、薬剤組成、薬剤含有量の各構成の何れかが上記の数値の範囲外となる場合には、このような官能性の効果が発現し難い場合がある。なお、本発明に係るティシュペーパーの製造方法において、上記坪量、紙厚とするには、ティシュペーパー原紙の坪量、抄造時のクレープ率、保湿薬液の粘度、塗布量を調整すればよい。 The tissue paper according to the present invention is particularly excellent in “softness”, “smoothness”, and “softness”, and the feeling of drug application such as “wetness”, “moistness”, and “stickiness” is extremely reduced. Will be. When any one of the above-described configurations of the number of plies, basis weight, paper thickness, drug composition, and drug content is outside the range of the above numerical values, such a functional effect may be difficult to be exhibited. In addition, in the manufacturing method of the tissue paper which concerns on this invention, what is necessary is just to adjust the basic weight of tissue paper base paper, the crepe rate at the time of papermaking, the viscosity of a moisturizing chemical | medical solution, and application quantity in order to set it as the said basic weight and paper thickness.
　また、本実施形態に係るティシュペーパーにおいて官能性の観点から好ましいグリセリンと１，３－プロパンジオールの質量比は、１：０．０４以上１：０．２１以下である。よって、本発明に係るティシュペーパーの製造方法における保湿薬液のグリセリンと１，３－プロパンジオールの好ましい質量比は、１：０．０４以上１：０．２１以下である。 In the tissue paper according to this embodiment, the mass ratio of glycerin and 1,3-propanediol that is preferable from the viewpoint of functionality is 1: 0.04 or more and 1: 0.21 or less. Therefore, a preferred mass ratio of glycerin and 1,3-propanediol in the moisturizing liquid in the method for producing tissue paper according to the present invention is 1: 0.04 or more and 1: 0.21 or less.
　また、本実施形態に係るティシュペーパーでは、官能性の観点から特に１．３－プロパンジオールの紙中比が、０．１３質量％超１．７０質量％未満であるのが望ましい。上記範囲であると１，３－プロパンジオールによる「ウェット感」、「湿り感」、「ベタツキ感」の低減、また、汎用タイプのようなさらっとした乾燥感と「滑らかさ」がより確実に発現し易くなる。 In the tissue paper according to the present embodiment, it is desirable that the ratio of 1.3-propanediol in the paper is more than 0.13% by mass and less than 1.70% by mass from the viewpoint of functionality. Within the above range, 1,3-propanediol reduces the “wetness”, “wetness” and “stickiness”, and the dryness and “smoothness” of the general-purpose type are more reliable. It becomes easy to express.
　他方、本発明に係るティシュペーパーは、縦方向の伸び率が、１０．０％以上１２．９％以下、好ましくは１０．０％以上１２．１％以下であるのが望ましい。伸び率がこの範囲にあると、洟かみの際などの使用時に十分な強度及び使用感を発現し易くなる。また、伸び率は、表面に微細なクレープを有するティシュペーパーの表面性とも関係があり、上記伸び率であると、表面の滑らかさがより確実に発現し易くなる。なお、この伸び率は、ＪＩＳ　Ｐ　８１１３（１９９８）の引張試験に従って測定した値をいう。測定装置としては、ミネベア株式会社製「万能引張圧縮試験機　ＴＧ－２００Ｎ」が挙げられる。また、伸び率は、ティシュペーパー原紙の抄紙時におけるクレープ率により調整することができる。 On the other hand, the tissue paper according to the present invention has a longitudinal elongation of 10.0% to 12.9%, preferably 10.0% to 12.1%. When the elongation percentage is within this range, sufficient strength and a feeling of use are easily exhibited during use such as when biting. Further, the elongation rate is also related to the surface property of the tissue paper having a fine crepe on the surface. In addition, this elongation rate means the value measured according to the tension test of JISP8113 (1998). Examples of the measuring apparatus include “Universal Tensile and Compression Tester TG-200N” manufactured by Minebea Co., Ltd. The elongation rate can be adjusted by the crepe rate at the time of paper making of the tissue paper.
　他方、本発明に係るティシュペーパーは、２プライのＣＤ方向の乾燥引張強度が９０ｃＮ／２５ｍｍ以上１２０ｃＮ／２５ｍｍ以下、好ましくは９２ｃＮ／２５ｍｍ以上１１６ｃＮ／２５ｍｍ以下であり、２プライのＣＤ方向の湿潤引張強度が３５ｃＮ／２５ｍｍ以上６０ｃＮ／２５ｍｍ以下、好ましくは４０ｃＮ／２５ｍｍ以上５３ｃＮ／２５ｍｍ以下であり、２プライのＣＤ方向の乾燥引張強度に対する２プライのＣＤ方向の湿潤引張強度の比が、０．４０以上であるのが望ましい。なお、ＣＤ方向とは、紙の横方向とも呼ばれ、抄紙の際の流れ方向（ＭＤ方向）に直行する方向である。また、乾燥引張強度は、ＪＩＳ Ｐ ８１１３に規定されるものであり、湿潤引張強度は、ＪＩＳ　Ｐ　８１３５（１９９８）に規定されるものである。上記の各強度であれば、使用に耐えうる十分な強さを発揮でき、また、使用者に「丈夫さ（強度・安心感）」を与えるものとなる。 On the other hand, the tissue paper according to the present invention has a dry tensile strength in the CD direction of 2 plies of 90 cN / 25 mm or more and 120 cN / 25 mm or less, preferably 92 cN / 25 mm or more and 116 cN / 25 mm or less. The strength is 35 cN / 25 mm or more and 60 cN / 25 mm or less, preferably 40 cN / 25 mm or more and 53 cN / 25 mm or less, and the ratio of the wet tensile strength in the CD direction of 2 plies to the dry tensile strength in the CD direction of 2 plies is 0.40. The above is desirable. Note that the CD direction is also called a paper lateral direction, and is a direction orthogonal to the flow direction (MD direction) during papermaking. The dry tensile strength is defined in JIS P8113, and the wet tensile strength is defined in JIS P8135 (1998). With each of the above strengths, sufficient strength to withstand use can be exhibited, and the user can be provided with “sturdiness (strength / security)”.
　また、本発明に係るティシュペーパーでは、２プライのＣＤ方向の乾燥引張強度に対する２プライのＣＤ方向の湿潤引張強度の比が、０．４０以上であり、一般的な保湿ティシューに比して、乾燥時と湿潤時における強度差が比較的小さい。このような強度差であることにより、特に洟をかむ際などに、乾燥時から湿潤時へと変化する使用態様において、使用者が「丈夫さ（強度・安心感）を感じるようになる。さらに、そのような使用態様における紙の強さの変化が感じられ難くなり、使用の際に「滑らかさ」が変化する違和感を感ずることもなくなる。 Moreover, in the tissue paper according to the present invention, the ratio of the wet tensile strength in the CD direction of the two plies to the dry tensile strength in the CD direction of the two plies is 0.40 or more, compared to a general moisturizing tissue, The strength difference between dry and wet is relatively small. Such a difference in strength makes it possible for the user to feel “sturdiness (strength / reassurance) in a usage mode that changes from dry to wet, especially when biting a heel. The change in the strength of the paper in such a usage mode becomes difficult to be felt, and the sense of incongruity that the “smoothness” changes during use is not felt.
　本発明に係るティシュペーパーにおいて、乾燥引張強度及び湿潤引張強度を上記値に調整するにあたっては、乾燥紙力増強剤や湿潤紙力増強剤を紙料或いは湿紙に内添することができる。乾燥紙力増強剤としては、澱粉、ポリアクリルアミド、ＣＭＣ（カルボキシメチルセルロース）若しくはその塩であるカルボキシメチルセルロースナトリウム、カルボキシメチルセルロースカルシウム、カルボキシメチルセルロース亜鉛等を用いることができる。湿潤紙力増強剤としては、ポリアミドポリアミンエピクロルヒドリン樹脂、尿素樹脂、酸コロイド・メラミン樹脂、熱架橋性塗工ＰＡＭ等を用いることができる。なお、乾燥紙力増強剤を内添する場合、パルプスラリーに対する添加量は、１．０ｋｇ／パルプｔ以下程度である。また、湿潤紙力増強剤は、カチオン性のものが望ましく、そのパルプスラリーに対する添加量は、５．０～２０．０ｋｇ／パルプｔ程度である。 In the tissue paper according to the present invention, when adjusting the dry tensile strength and the wet tensile strength to the above values, a dry paper strength enhancer or a wet paper strength enhancer can be internally added to the stock or wet paper. As the dry paper strength enhancer, starch, polyacrylamide, CMC (carboxymethylcellulose) or a salt thereof such as sodium carboxymethylcellulose, carboxymethylcellulose calcium, carboxymethylcellulose zinc and the like can be used. As the wet paper strength enhancer, polyamide polyamine epichlorohydrin resin, urea resin, acid colloid / melamine resin, thermally crosslinkable coating PAM, and the like can be used. When a dry paper strength enhancer is internally added, the amount added to the pulp slurry is about 1.0 kg / pulp t or less. The wet paper strength enhancer is preferably a cationic one, and the amount added to the pulp slurry is about 5.0 to 20.0 kg / pulp t.
　他方、本発明に係るティシュペーパーでは、ＭＭＤが７．９未満、ソフトネスが１．０９ｃＮ／１００ｍｍ未満であるのが望ましい。特に好ましくは、ＭＭＤが７．７以下、ソフトネスが１．０３ｃＮ／１００ｍｍ以下である。ＭＭＤは、表面の「滑らかさ」の指標の一つであり、上記範囲であれば十分に滑らかさが感じられる。また、ソフトネスは、「柔らかさ」の指標の一つであり、上記範囲であれば、保湿剤が含有されていない汎用タイプのティシュペーパーとの「柔らかさ」の差が感じられ易く、また、コシも感じられるものとなる。本実施形態に係るティシュペーパーでは、本発明のプライ数、坪量、紙厚、薬剤組成、薬剤含有量とすることで、上記ＭＭＤ及びソフトネスを達成できる。さらなる調整は、パルプ組成、製造時のクレープ率によって行うことができる。 On the other hand, in the tissue paper according to the present invention, it is desirable that the MMD is less than 7.9 and the softness is less than 1.09 cN / 100 mm. Particularly preferably, the MMD is 7.7 or less and the softness is 1.03 cN / 100 mm or less. MMD is one of the indices of “smoothness” of the surface, and if it is in the above range, the smoothness is felt sufficiently. Softness is one of the indices of “softness”, and within the above range, it is easy to feel the difference in “softness” from a general-purpose tissue paper that does not contain a moisturizing agent. , Koshi will be felt. In the tissue paper according to the present embodiment, the MMD and softness can be achieved by setting the number of plies, basis weight, paper thickness, drug composition, and drug content of the present invention. Further adjustments can be made by pulp composition and crepe rate during production.
　なお、ＭＭＤは摩擦係数の平均偏差であり、数値が小さいほど滑らかであり、数値が大きいほど滑らかさに劣るとされる。ＭＭＤの測定方法は、摩擦子の接触面を所定方向に２０ｇ／ｃｍの張力が付与された測定試料の表面に対して２５ｇの接触圧で接触させながら、張力が付与された方向と略同じ方向に速度０．１ｃｍ／ｓで２ｃｍ移動させ、このときの、摩擦係数を、摩擦感テスター　ＫＥＳ－ＳＥ（カトーテック株式会社製）を用いて測定する。その摩擦係数を摩擦距離（移動距離＝２ｃｍ）で除した値がＭＭＤである。なお、摩擦子は、直径０．５ｍｍのピアノ線Ｐを２０本隣接させてなり、長さ及び幅がともに１０ｍｍとなるように形成された接触面を有している。接触面には、先端が２０本のピアノ線Ｐ（曲率半径０．２５ｍｍ）で形成された単位膨出部が形成されているものとした。 Note that MMD is the average deviation of the friction coefficient. The smaller the value, the smoother the value, and the larger the value, the less smooth. In the MMD measurement method, the contact surface of the friction element is brought into contact with the surface of the measurement sample to which a tension of 20 g / cm is applied in a predetermined direction at a contact pressure of 25 g, and is substantially the same as the direction in which the tension is applied. The friction coefficient at this time is measured using a friction tester KES-SE (manufactured by Kato Tech Co., Ltd.). The value obtained by dividing the friction coefficient by the friction distance (movement distance = 2 cm) is MMD. In addition, the friction element has 20 piano wires P having a diameter of 0.5 mm adjacent to each other, and has a contact surface formed so that the length and the width are both 10 mm. The contact surface is assumed to have a unit bulge portion formed with 20 piano wires P (curvature radius 0.25 mm) at the tip.
　また、ソフトネスは、ＪＩＳ　Ｌ　１０９６　Ｅ法に準じたハンドルオメータ法に従って測定した値である。但し、試験片は１００ｍｍ×１００ｍｍの大きさとし、クリアランスは５ｍｍとして実施する。１プライで縦方向、横方向の各々５回ずつ測定し、その全１０回の平均値を、ｃＮ／１００ｍｍを単位として表す。 Softness is a value measured according to the handle ohm method according to JIS L 1096 E method. However, the test piece is 100 mm × 100 mm in size, and the clearance is 5 mm. The measurement is performed 5 times each in the longitudinal direction and the lateral direction with 1 ply, and the average value of all 10 times is expressed in units of cN / 100 mm.
　次いで、以上説明の本実施形態に係るティシュペーパーが低塗布量であっても、その「柔らかさ」、「ふんわり感」、「ウェット感・湿り感」において優れるものであることを、さらに、「実施例」を参照して説明する。 Next, even if the tissue paper according to the present embodiment described above is a low coating amount, it is excellent in its “softness”, “soft feeling”, “wet feeling / moist feeling”, and “ This will be described with reference to “Examples”.
　本発明に係るティシュペーパー及び本発明とは異なるティシュペーパーに係る試験試料を作成し、「柔らかさ」、「ふんわり感」、「ウェット感・湿り感」を評価項目として、下記官能試験を行ない検討した。各例を製造するにあたって、保湿薬液の塗布は、ロータリー式インターフォルダに組み込んだフレキソ印刷機により行なった。各試料の物性値・組成値等は、下記のとおり測定した。各試料の物性値・組成値及び試験結果は、下記表１示されるとおりである。 Prepare test papers related to the tissue paper according to the present invention and tissue papers different from the present invention, and perform the following sensory tests with the evaluation items of “soft”, “soft”, “wet / wet” did. In manufacturing each example, the moisturizing chemical was applied by a flexographic printing machine incorporated in a rotary interfolder. The physical properties and composition values of each sample were measured as follows. The physical property values, composition values, and test results of each sample are as shown in Table 1 below.
〔坪量〕
　ＪＩＳ　Ｐ　８１２４（１９９８）に従って測定した。表中の値は、各プライの平均値である。 [Basis weight]
It was measured according to JIS P 8124 (1998). The values in the table are average values for each ply.
〔紙厚〕
　ＪＩＳ　Ｐ　８１１１（１９９８）の条件下で、ダイヤルシックネスゲージ（厚み測定器）「ＰＥＡＣＯＣＫ　Ｇ型」（尾崎製作所製）を用いて上述の厚みの測定方法に従って測定した。 [Paper thickness]
Under the conditions of JIS P 8111 (1998), the thickness was measured according to the thickness measurement method described above using a dial thickness gauge (thickness measuring instrument) “PEACOCK G type” (manufactured by Ozaki Seisakusho).
〔密度〕
　密度は、ＪＩＳ　Ｐ　８１１１（１９９８）　条件下において調湿させたティシュペーパーの坪量を２倍した値（Ｃ）を、上述のティシュペーパー（２プライ）の紙厚（Ｄ）で除した値で、単位をｇ／ｃｍ3、小数点３桁で表した。 〔density〕
The density is a value obtained by dividing a value (C) obtained by doubling the basis weight of tissue paper conditioned under the conditions of JIS P 8111 (1998) by the paper thickness (D) of the above-described tissue paper (2 plies). The unit is g / cm 3 , and the decimal point is 3 digits.
〔乾燥引張強度〕
　ＪＩＳ　Ｐ　８１１３（１９９８）の引張試験に従って測定した。 [Dry tensile strength]
It was measured according to the tensile test of JIS P 8113 (1998).
〔湿潤引張強度〕
　ＪＩＳ　Ｐ　８１３５（１９９８）の引張試験に従って測定した。 (Wet tensile strength)
It was measured according to the tensile test of JIS P 8135 (1998).
〔伸び率〕
　ＪＩＳ　Ｐ　８１１３（１９９８）の引張試験に従って、ミネベア株式会社製「万能引張圧縮試験機　ＴＧ－２００Ｎ」を用いて測定した。 〔Growth rate〕
According to the tensile test of JIS P 8113 (1998), the measurement was performed using “Universal Tensile Compression Tester TG-200N” manufactured by Minebea Co., Ltd.
〔ソフトネス〕
　ＪＩＳ　Ｌ　１０９６　Ｅ法に準じたハンドルオメータ法に従って測定した。但し、試験片は１００ｍｍ×１００ｍｍの大きさとし、クリアランスは５ｍｍとして実施した。１プライで縦方向、横方向の各々５回ずつ測定し、その全１０回の平均値を、ｃＮ／１００ｍｍを単位として表した。 [Softness]
It measured according to the handle ohm method according to JISL1096E method. However, the test piece was 100 mm × 100 mm in size, and the clearance was 5 mm. One ply was measured 5 times each in the vertical direction and the horizontal direction, and the average value of all 10 times was expressed in units of cN / 100 mm.
〔ＭＭＤ〕
　摩擦子の接触面を所定方向に２０ｇ／ｃｍの張力が付与された測定試料の表面に対して２５ｇの接触圧で接触させながら、張力が付与された方向と略同じ方向に速度０．１ｃｍ／ｓで２ｃｍ移動させ、このときの、摩擦係数を、摩擦感テスター　ＫＥＳ－ＳＥ（カトーテック株式会社製）を用いて測定し、の摩擦係数を摩擦距離（移動距離＝２ｃｍ）で除した値とした。摩擦子は、直径０．５ｍｍのピアノ線Ｐを２０本隣接させてなり、長さ及び幅がともに１０ｍｍとなるように形成された接触面を有している。接触面には、先端が２０本のピアノ線Ｐ（曲率半径０．２５ｍｍ）で形成された単位膨出部が形成されているものとした。 [MMD]
While the contact surface of the friction element is brought into contact with the surface of the measurement sample to which a tension of 20 g / cm is applied in a predetermined direction at a contact pressure of 25 g, a speed of 0.1 cm / cm is applied in substantially the same direction as the tension is applied. The friction coefficient at this time was measured using a friction feeling tester KES-SE (manufactured by Kato Tech Co., Ltd.), and the friction coefficient was divided by the friction distance (movement distance = 2 cm). did. The friction element is formed by adjoining 20 piano wires P having a diameter of 0.5 mm, and has a contact surface formed so that the length and the width are both 10 mm. The contact surface is assumed to have a unit bulge portion formed with 20 piano wires P (curvature radius 0.25 mm) at the tip.
〔薬剤含有量〕
　薬剤含有量は、絶乾時の試料中の薬剤の量である。なお、絶乾時とは、温度６５℃、湿度１０％で恒量となるまで乾燥させた状態における薬剤の量である。 [Drug content]
The drug content is the amount of drug in the sample when absolutely dry. In addition, the time of absolute dry is the quantity of the chemical | medical agent in the state dried until it became constant weight at the temperature of 65 degreeC and the humidity of 10%.
〔薬剤含有率（絶乾）〕
　薬剤含有率（絶乾）は、絶乾時の試料中に含まれる薬剤の割合である。 [Drug content (absolute dryness)]
The drug content (absolute dryness) is the ratio of the drug contained in the sample at the absolute dryness.
〔薬剤含有率（水分含）〕
　薬剤含有率（水分含）は、温度２３℃、湿度５０％の条件下で２４時間、調湿した状態における試料中に含まれる薬剤（水分を含む）の割合である。なお、薬剤の量は、調湿した状態の試料の質量と絶乾時の試料の質量と、上記薬剤含有量とから算出する。 [Drug content (including water)]
The drug content (including water) is the ratio of the drug (including water) contained in the sample in a condition of being conditioned for 24 hours under conditions of a temperature of 23 ° C. and a humidity of 50%. The amount of the drug is calculated from the mass of the sample in a conditioned state, the mass of the sample when absolutely dry, and the drug content.
〔１，３－プロパンジオールの紙中比率〕
　１，３－プロパンジオールの紙中比率は、絶乾時の試料の質量に対する１，３－プロパンジオールの質量の割合である。 [Ratio of 1,3-propanediol in paper]
The ratio of 1,3-propanediol in paper is the ratio of the mass of 1,3-propanediol to the mass of the sample when absolutely dry.
〔官能試験〕
　評価者を３０人とし、薬剤を含まないティシュペーパーである比較例３を基準試料として、その基準試料との比較で「柔らかさ」、「ふんわり感」、「ウェット感、湿り感」について、「大変優れている」と感じたものについて「５」、「優れている」と感じたものについて「４」、「優れるとも劣るとも言えない」と感じたものについては「３」、「悪い」と感じたものについては「２」、「非常に悪い」と感じたものについては「１」と評価し、各評価者の平均点を算出したものを評価値とした。また、「総合評価」は、「肌触りが良く、購入意向が大変高い」と感じたものについては「５」、「肌触りが良く、購入意向が高い」と感じたものについては「４」、「肌触りは普通で、購入意向が高いとも低いとも言えない」と感じたものについては「３」、「肌触りに劣り、購入意向が低い」と感じたものについては「２」、「肌触りが非常に劣り、購入意向はほぼない」と感じたものについては「１」と評価したもので、各評価者の平均点を算出したものを評価値とした。なお、比較例３は、薬剤を含有する本発明の実施例である実施例１から実施例１１及び比較例４から比較例１０における薬液を付与する前の原紙に相当するものである。 [Sensory test]
There were 30 evaluators, and Comparative Example 3 which is a tissue paper containing no drug was used as a reference sample, and compared with the reference sample, “softness”, “soft feeling”, “wet feeling, wet feeling” “5” for those who felt “excellent”, “4” for those who felt “excellent”, “3” for those who felt “not good or inferior”, “bad” What was felt was evaluated as “2”, and what was felt as “very bad” was evaluated as “1”, and the average score of each evaluator was calculated as an evaluation value. In addition, “Comprehensive evaluation” is “5” for those who feel “good touch and very high intention to purchase”, “4” for those who feel “good touch and high intention to purchase”, “ “3” for those who feel that the touch is normal, and that the purchase intention is high or low can be said to be “3”; for those that feel that “the touch is poor and the purchase intention is low”, “2”, “the touch is very Those who felt that they were inferior and almost not intending to purchase were evaluated as “1”, and the average score of each evaluator was calculated as the evaluation value. In addition, the comparative example 3 is corresponded to the base paper before giving the chemical | medical solution in Example 1 to Example 11 and Comparative Example 4 to Comparative Example 10 which are the Examples of this invention containing a chemical | medical agent.
Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000001
〔試験結果〕
　試験結果に関しては、表１及び表１に示される実施例１から実施例７及び比較例３～比較例８における官能評価をグラフ化した図２を参照して説明する。なお、図２の横軸は、１，３－プロパンジオールの薬剤含有量に対応し、縦軸は官能評価に対応する。 〔Test results〕
The test results will be described with reference to FIG. 2 in which the sensory evaluations in Examples 1 to 7 and Comparative Examples 3 to 8 shown in Table 1 and Table 1 are graphed. In FIG. 2, the horizontal axis corresponds to the drug content of 1,3-propanediol, and the vertical axis corresponds to sensory evaluation.
　表１における各試料は、比較例１～比較例３が保湿剤を含まない非保湿系ティシュペーパーであり、これらは、坪量及び紙厚が異なっている。これらの比較では、坪量及び紙厚が低下するにしたがって、「ウェット感・湿り感」が改善されるが「柔らかさ」、「ふんわり感」が低下している傾向があるが、何れにおいても、購入意欲が低い。 Each sample in Table 1 is a non-moisturizing tissue paper in which Comparative Examples 1 to 3 do not contain a moisturizing agent, and these differ in basis weight and paper thickness. In these comparisons, as the basis weight and paper thickness decrease, the “wetness / moistness” improves, but the “softness” and “softness” tend to decrease. , Low willingness to buy.
　比較例４は、１，３－プロパンジオールを含まない従来のグリセリンのみを主たる効果成分とする薬剤、つまり１，３－プロパンジオールの比率が０の薬剤が１．０ｇ／ｍ2含有されているものである。比較例４は、従来のグリセリンのみを主たる効果成分としつつ薬剤含有量を実施例１～実施例２と同程度に低くしている。この比較例４と基準試料である比較例３を対比してみると、低い薬剤含有量により「ウェット感・湿る感」は低下していない。また、「柔らかさ」は若干向上している。しかし、それと引き替えに「ふんわり感」も若干低下していることが確認できる。 Comparative Example 4 contains 1.0 g / m 2 of a drug mainly containing conventional glycerin not containing 1,3-propanediol, that is, a drug having a 1,3-propanediol ratio of 0. Is. Comparative Example 4 has the drug content as low as that of Examples 1 and 2 while using only conventional glycerin as the main effective ingredient. When this Comparative Example 4 is compared with Comparative Example 3 which is a reference sample, the “wet feeling / moist feeling” does not decrease due to the low drug content. In addition, “softness” is slightly improved. However, it can be confirmed that the “soft feeling” is slightly reduced in exchange.
　また、比較例５、比較例６は、薬剤含有量については比較例４と同じであるが、グリセリンと１，３－プロパンジオールを含む薬剤を用いている。但し、グリセリンと１，３－プロパンジオールの質量比が本発明と異なり、特に１．３プロパンジオールの割合が本発明より低い。なお、比較例５、比較例６とでは比較例６のほうが１，３－プロパンジオールの比率が高いものである。比較例４～比較例６を対比してみると、１，３－プロパンジオールの紙中比率が高まるにつれて「ふんわり感」が改善され、また、その割合が高まるにつれて、「柔らかさ」も向上している。「ウェット感・湿り感」も低下していない。しかし、比較例６程度の紙中比率では、「柔らかさ」及び「ふんわり感」が個別的には向上しているものの、劇的な向上は確認できず、総合評価（購入意欲）については、さほどたかまっていない。つまり、保湿ティシューペーパーとして十分なものとはなっていない。 Further, Comparative Example 5 and Comparative Example 6 have the same drug content as Comparative Example 4, but use a drug containing glycerin and 1,3-propanediol. However, the mass ratio of glycerin and 1,3-propanediol is different from that of the present invention, and the ratio of 1.3 propanediol is particularly lower than that of the present invention. In Comparative Examples 5 and 6, Comparative Example 6 has a higher ratio of 1,3-propanediol. Comparing Comparative Example 4 to Comparative Example 6, “softness” improves as the ratio of 1,3-propanediol in the paper increases, and “softness” also increases as the ratio increases. ing. "Wet feeling and wet feeling" has not decreased. However, although the “softness” and the “soft feeling” are individually improved at the ratio in the paper of about Comparative Example 6, a dramatic improvement cannot be confirmed, and the overall evaluation (motivation to purchase) is as follows. Not so much. In other words, it is not sufficient as a moisturizing tissue paper.
　次に、これらの比較例４～比較例６と本発明の実施例１とを対比してみると、実施例１は、比較例４～６と薬剤含有率が同じにもかかわらず、「柔らかさ」及び「ふんわり感」において顕著な向上が確認できる。総合評価（購入意欲）も高まっていることが確認できる。 Next, comparing these Comparative Example 4 to Comparative Example 6 with Example 1 of the present invention, Example 1 is “soft” despite the same drug content as Comparative Examples 4 to 6. Significant improvements can be confirmed in “sa” and “soft”. It can be confirmed that overall evaluation (motivation to purchase) is also increasing.
　さらに、実施例１～実施例１１をみてみる。実施例１から実施例１１に向かって薬剤含有量が増加している。なお、実施例６と実施例７、実施例１０と実施例１１は、薬剤含有量がそれぞれ同量となっている。これらの実施例を対比してみると実施例１から実施例２、実施例３、実施例４、実施例５に向かうにしたがって、「柔らかさ」、「ふんわり感」、「ウェット感・湿り感」の評価が高まる傾向にあり、さらに実施例５から実施例８まで非常に高い評価が続く。実施例９からやや評価が低下する傾向が見られる。総合評価（購入意欲）も実施例５～実施例８がピークとなっている。また、実施例１～１１においてはＭＭＤ、ソフトネスについては十分に満足する結果が得られている。 Further, look at Example 1 to Example 11. The drug content increases from Example 1 to Example 11. In addition, Example 6 and Example 7, Example 10 and Example 11 respectively have the same drug content. In contrast to these examples, as they go from Example 1 to Example 2, Example 3, Example 4, and Example 5, “softness”, “softness”, “wetness / wetness” ”And the evaluation is very high from Example 5 to Example 8. From Example 9, there is a tendency for the evaluation to decrease slightly. The overall evaluation (motivation to purchase) also peaks in Examples 5 to 8. In Examples 1 to 11, sufficiently satisfactory results were obtained for MMD and softness.
　続けて、実施例１１と比較例７～比較例８とを対比してみると、まず、比較例７は、実施例１１より１，３－プロパンジオールの割合が高く、本発明の範囲外になっているものである。比較例８は、比較例７よりもさらに１，３－プロパンジオールの割合が高いものである。これらを対比してみると、比較例７は、グリセリンの配合量も十分で、１，３－プロパンジオールの割合も高くなっているにも関わらず、実施例１０～実施例１１よりも「柔らかさ」及び「ふんわり感」の評価の落ち込みが激しい。「ウェット感・湿り感」の評価も急激に落ちている。さらに、比較例１１は、薬剤含有量及び１，３－プロパンジオールの割合が比較例７よりも高いものであるが、比較例８では「柔らかさ」、「ふんわり感」の評価が急激に落ちている。 Subsequently, comparing Example 11 with Comparative Examples 7 to 8, first, Comparative Example 7 has a higher proportion of 1,3-propanediol than Example 11 and is outside the scope of the present invention. It is what has become. Comparative Example 8 has a higher proportion of 1,3-propanediol than Comparative Example 7. Comparing these, Comparative Example 7 is “softer” than Examples 10 to 11 despite the sufficient amount of glycerin and the high proportion of 1,3-propanediol. The drop in the evaluation of “sa” and “softness” is severe. The evaluation of “wetness / moistness” has also fallen sharply. Further, in Comparative Example 11, the drug content and the proportion of 1,3-propanediol are higher than those in Comparative Example 7, but in Comparative Example 8, the evaluations of “softness” and “soft feeling” drop sharply. ing.
　さらに、比較例９及び比較例１０をみてみる。比較例９は、１，３－プロパンジオールを含まない従来のグリセリンのみを主たる効果成分とする薬剤を、２．６ｇ／ｍ2含有するものであり、比較例１０は、従来のグリセリンのみを主たる効果成分とする薬剤が６．３ｇ／ｍ2含有するものである。比較例９では、「柔らかさ」については基準試料である比較例３より評価が高く、「ふんわり感」については同等、「ウェット感・湿る感」については評価が低い。比較例１０は、すべての評価項目で低い。比較例９は、従来市販品よりもやや薬剤含有量を低くしているものの比較例４程度に比べれば高い、つまり、従来のグリセリンのみを主たる効果成分の薬剤では、「柔らかさ」、「ふんわり感」、「べたつき感」の両立ができないことが示されている。比較例１０は、従来市販品と同程度の薬剤含有量であるが、従来市販品では、通常、本発明に係る坪量よりも高いため、これが影響していると思われる。 Further, Comparative Example 9 and Comparative Example 10 will be examined. Comparative Example 9 contains 2.6 g / m 2 of a drug containing, as a main effective ingredient, only conventional glycerin that does not contain 1,3-propanediol, and Comparative Example 10 mainly contains only conventional glycerin. The drug as an effective ingredient contains 6.3 g / m 2 . In Comparative Example 9, “softness” is higher in evaluation than Comparative Example 3 as a reference sample, “soft feeling” is equivalent, and “wet feeling / moist feeling” is low in evaluation. The comparative example 10 is low in all evaluation items. Comparative Example 9 has a slightly lower drug content than that of a conventional commercial product, but is higher than that of Comparative Example 4, that is, “softness”, “ It is shown that it is impossible to achieve both “feel” and “stickiness”. Although the comparative example 10 is a chemical | medical agent content comparable as a conventional commercial item, since it is higher than the basic weight which concerns on this invention in the conventional commercial item, this seems to have influenced.
　以上のことから、本発明に係る保湿薬液を用いることにより保湿薬液の塗布量を非常に少なくしても、「柔らかさ」、「ふんわり感」において顕著に優れ、洟かみに頻繁に使用するなど繰り返し肌を清拭しても肌に対する負荷が少ないうえ、さらに「ウェット感」、「湿り感」、「ベタツキ感」といった薬剤塗布感も顕著に低減されるものとなる。 From the above, even if the application amount of the moisturizing chemical solution is very small by using the moisturizing chemical solution according to the present invention, it is remarkably excellent in “softness” and “soft feeling”, and frequently used for itching. Even if the skin is repeatedly wiped, the load on the skin is small, and the feeling of drug application such as “wet feeling”, “moist feeling”, and “stickiness” is also significantly reduced.
　また、本発明の実施例においては、ロータリー式インターフォルダによる製造過程において特段の問題を称することなく安定して製造が可能であった。してみれば、本発明に係るこの保湿薬液を用いるティシュペーパーの製造方法によれば、特にロータリー式インターフォルダにおける高速化が可能となる。 Further, in the embodiment of the present invention, stable production was possible without referring to any particular problem in the production process by the rotary type interfolder. Thus, according to the tissue paper manufacturing method using this moisturizing chemical solution according to the present invention, it is possible to increase the speed especially in the rotary type interfolder.
　１・・・ロータリー式インターフォルダ、１０…折り畳み機構部、１１…フォールディングロール、１２…ナイフロール、１３…フレキソ印刷機、２０…原反ロール、２１…積層ティシュペーパー原紙、３０…束。 DESCRIPTION OF SYMBOLS 1 ... Rotary type | system | group interfolder, 10 ... Folding mechanism part, 11 ... Folding roll, 12 ... Knife roll, 13 ... Flexographic printing machine, 20 ... Original fabric roll, 21 ... Laminated tissue paper base paper, 30 ... Bundle.

Claims (2)

  1. 　ロータリー式インターフォルダにおいて、帯状のティシュペーパー原紙を積層した２プライの積層ティシュペーパー原紙に対して、
    　グリセリンと１，３－プロパンジオールを主成分とし、グリセリンと１，３－プロパンジオールの質量比が１：０．０３超１：０．２５未満である保湿薬液を、有効成分量で１．０ｇ／ｍ2以上２．２ｇ／ｍ2未満塗布する工程を有する、ことを特徴とするティシュペーパー製品の製造方法。     In the rotary type interfolder, for the two-ply laminated tissue paper base paper, which is a stack of belt-shaped tissue paper base paper,
    1.0 g of a moisturizing liquid containing glycerin and 1,3-propanediol as main components and having a mass ratio of glycerin to 1,3-propanediol of more than 1: 0.03 and less than 1: 0.25 in an amount of active ingredients. / m with two or more 2.2 g / m 2 less coating to method of manufacturing an tissue paper product characterized in that.
  2. 　保湿薬液を塗布した後のティシュペーパー原紙の坪量を、１１．８ｇ／ｍ2以上１３．０ｇ／ｍ2以下、２プライでの紙厚を１２５μｍ以上１３５μｍ以下とする、請求項１記載のティシュペーパー製品の製造方法。 The tissue according to claim 1, wherein the basis weight of the tissue paper after applying the moisturizing liquid is 11.8 g / m 2 or more and 13.0 g / m 2 or less, and the paper thickness at 2 plies is 125 µm or more and 135 µm or less. Paper product manufacturing method.
PCT/JP2016/088025 2016-03-31 2016-12-21 Manufacturing method for tissue-paper product WO2017168877A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016-073199 2016-03-31
JP2016073199A JP6174748B1 (en) 2016-03-31 2016-03-31 Manufacturing method of tissue paper products

Publications (1)

Publication Number Publication Date
WO2017168877A1 true WO2017168877A1 (en) 2017-10-05

Family

ID=59505217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/088025 WO2017168877A1 (en) 2016-03-31 2016-12-21 Manufacturing method for tissue-paper product

Country Status (2)

Country Link
JP (1) JP6174748B1 (en)
WO (1) WO2017168877A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011152426A (en) * 2009-12-28 2011-08-11 Daio Paper Corp Method of manufacturing secondary whole roll for tissue paper product
JP2011156120A (en) * 2010-01-29 2011-08-18 Daio Paper Corp Tissue and method of manufacturing tissue
JP2013511509A (en) * 2009-11-20 2013-04-04 キンバリー クラーク ワールドワイド インコーポレイテッド Temperature change composition and tissue product that give a cooling feeling
JP2013227707A (en) * 2012-03-30 2013-11-07 Daio Paper Corp Tissue paper having chemical solution imparted thereto and method for producing tissue paper having chemical solution imparted thereto

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013511509A (en) * 2009-11-20 2013-04-04 キンバリー クラーク ワールドワイド インコーポレイテッド Temperature change composition and tissue product that give a cooling feeling
JP2011152426A (en) * 2009-12-28 2011-08-11 Daio Paper Corp Method of manufacturing secondary whole roll for tissue paper product
JP2011156120A (en) * 2010-01-29 2011-08-18 Daio Paper Corp Tissue and method of manufacturing tissue
JP2013227707A (en) * 2012-03-30 2013-11-07 Daio Paper Corp Tissue paper having chemical solution imparted thereto and method for producing tissue paper having chemical solution imparted thereto

Also Published As

Publication number Publication date
JP2017176760A (en) 2017-10-05
JP6174748B1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
JP4868620B2 (en) Tissue paper and tissue paper manufacturing method
CN107105947B (en) Tissue paper
JP4786764B2 (en) Tissue paper product and method for manufacturing tissue paper product
JP5985804B2 (en) Moisturizing tissue paper product and method for producing moisturizing tissue paper
TWI783924B (en) facial tissue
JP5859593B2 (en) Tissue paper products
TWI740025B (en) Facial tissue and manufacturing method of facial tissue products
JP4868621B1 (en) Tissue paper products
JP4868625B2 (en) Tissue paper and tissue paper manufacturing method
CN107109802B (en) Tissue paper
JP5514967B1 (en) Tissue paper products
JP6174748B1 (en) Manufacturing method of tissue paper products
JP5512755B2 (en) Tissue paper products
JP6400996B2 (en) Production method of lotion tissue paper
JP4868622B2 (en) Tissue paper and tissue paper manufacturing method
TWI781156B (en) Manufacturing method of facial paper and facial paper products
JP4868624B1 (en) Tissue paper products
JPWO2011080939A1 (en) Tissue paper and tissue paper manufacturing method
JP2012024546A (en) Facial tissue product

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16897093

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 16897093

Country of ref document: EP

Kind code of ref document: A1